Home > EMCDDA–Europol Joint Report on a new psychoactive substance: N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA).

(2017) EMCDDA–Europol Joint Report on a new psychoactive substance: N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA). Luxembourg: Publications Office of the European Union.

[img]
Preview
PDF (EMCDDA–Europol Joint Report on a new psychoactive substance) - Published Version
986kB

In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)- 1H-indazole-3-carboxamide, commonly known as AB-CHMINACA, through a joint assessment. The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 3 July 2017.

Item Type
Report
Publication Type
International, Guideline, Report
Drug Type
New psychoactive substance
Intervention Type
Harm reduction, Screening / Assessment
Date
11 September 2017
Pages
19 p.
Publisher
Publications Office of the European Union
Place of Publication
Luxembourg
EndNote
Accession Number
HRB (Electronic Only)

Repository Staff Only: item control page